{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:45:59Z","timestamp":1785527159514,"version":"3.56.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08658-1","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:48:16Z","timestamp":1784800096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing immunity against breast cancer: from checkpoints to cell therapies"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-7362","authenticated-orcid":false,"given":"Ali","family":"Mussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasin","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Talib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Hayati","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmawati","family":"Lambuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar Daku","family":"Bishir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz Anwer","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Lukman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruaa","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaldeen","family":"Yagoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Hajisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Fatmawati","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohimah","family":"Mohamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosline","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. I.","family":"Al-Hatamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"3","key":"8658_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clinicians"},{"key":"8658_CR2","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.drup.2025.101288","volume":"83","author":"G-Y Wu","year":"2025","unstructured":"Wu G-Y, Xiao M-Z, Hao W-C, Yang Z-S, Liu X-R, Xu D-S, et al. Drug resistance in breast cancer: mechanisms and strategies for management. Drug Resist Updates. 2025;83:101288. https:\/\/doi.org\/10.1016\/j.drup.2025.101288.","journal-title":"Drug Resist Updates"},{"issue":"18","key":"8658_CR3","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","volume":"28","author":"MM Gubin","year":"2022","unstructured":"Gubin MM, Vesely MD. Cancer immunoediting in the Era of Immuno-oncology. Clin Cancer Res. 2022;28(18):3917\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1804.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"8658_CR4","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.3390\/cancers13164233","volume":"13","author":"JJ Li","year":"2021","unstructured":"Li JJ, Tsang JY, Tse GM. Tumor microenvironment in breast cancer\u2014updates on Therapeutic implications and pathologic assessment. Cancers (Basel). 2021;13(16):4233. https:\/\/doi.org\/10.3390\/cancers13164233.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8658_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-024-03218-1","volume":"43","author":"A Mussa","year":"2024","unstructured":"Mussa A, Ismail NH, Hamid M, Al-Hatamleh MAI, Bragoli A, Hajissa K, et al. Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer. J Exp Clin Cancer Res. 2024;43(1):312. https:\/\/doi.org\/10.1186\/s13046-024-03218-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"8658_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151\u201367. https:\/\/doi.org\/10.1038\/s41571-018-0142-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"8658_CR7","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.3390\/ijms25137208","volume":"25","author":"L Yang","year":"2024","unstructured":"Yang L, Hu Q, Huang T. Breast cancer treatment strategies targeting the tumor microenvironment: how to convert \u201ccold\u201d tumors to \u201chot\u201d tumors. IJMS. 2024;25(13):7208. https:\/\/doi.org\/10.3390\/ijms25137208.","journal-title":"IJMS"},{"key":"8658_CR8","doi-asserted-by":"publisher","first-page":"1153990","DOI":"10.3389\/fimmu.2023.1153990","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023;14:1153990. https:\/\/doi.org\/10.3389\/fimmu.2023.1153990.","journal-title":"Front Immunol"},{"key":"8658_CR9","doi-asserted-by":"publisher","first-page":"103792","DOI":"10.1016\/j.breast.2024.103792","volume":"78","author":"L Ji","year":"2024","unstructured":"Ji L, Chen X, Qian X, Xiao M, Li Q, Li Q, et al. Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy. Breast. 2024;78:103792. https:\/\/doi.org\/10.1016\/j.breast.2024.103792.","journal-title":"Breast"},{"issue":"9","key":"8658_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"5","key":"8658_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","volume":"31","author":"P Schmid","year":"2020","unstructured":"Schmid P, Salgado R, Park YH, Mu\u00f1oz-Couselo E, Kim SB, Sohn J, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31(5):569\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.072.","journal-title":"Ann Oncol"},{"issue":"5","key":"8658_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 2020;6(5):676. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650.","journal-title":"JAMA Oncol"},{"key":"8658_CR13","doi-asserted-by":"publisher","unstructured":"Liu MC, Robinson PA, Yau C, Wallace AM, Chien AJ, Stringer-Reasor E, et al. Abstract P3-09-02: evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: results from the I-SPY 2 TRIAL. Cancer Res. 2020;80(4_Supplement):P3\u201309\u201302\u2013P3\u201309\u201302. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-P3-09-02.","DOI":"10.1158\/1538-7445.SABCS19-P3-09-02"},{"key":"8658_CR14","doi-asserted-by":"publisher","unstructured":"Schmid P, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, K\u00fcemmel S, et al. Abstract LBO1-01: neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: updated event-free survival results from the phase 3 KEYNOTE-522 study. Cancer Res. 2024;84(9_Supplement):LBO1\u201301\u2013LBO1\u201301. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-LBO1-01.","DOI":"10.1158\/1538-7445.SABCS23-LBO1-01"},{"key":"8658_CR15","doi-asserted-by":"publisher","unstructured":"Schmid P, Cort\u00e9s J, Dent RA, McArthur HL, Pusztai L, Kummel S, et al. LBA4 neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: overall survival results from the phase III KEYNOTE-522 study. Ann Oncol. 2024;35:S1204\u201305. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2247","DOI":"10.1016\/j.annonc.2024.08.2247"},{"issue":"5","key":"8658_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, Cortes J, Dent R, McArthur H, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35(5):429\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.002.","journal-title":"Ann Oncol"},{"issue":"6","key":"8658_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"issue":"2","key":"8658_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer. JAMA Oncol. 2024;10(2):227. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033.","journal-title":"JAMA Oncol"},{"issue":"10257","key":"8658_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"issue":"5","key":"8658_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP michelangelo randomized study. Ann Oncol. 2022;33(5):534\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.004.","journal-title":"Ann Oncol"},{"issue":"11","key":"8658_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J-U, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940.","journal-title":"Ann Oncol"},{"issue":"8","key":"8658_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279\u201388. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"issue":"19","key":"8658_CR23","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.3390\/cancers13194839","volume":"13","author":"T Iwase","year":"2021","unstructured":"Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, et al. A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer. Cancers. 2021;13(19):4839. https:\/\/doi.org\/10.3390\/cancers13194839.","journal-title":"Cancers"},{"issue":"16_suppl","key":"8658_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2023.41.16_suppl.102","volume":"41","author":"DM Wolf","year":"2023","unstructured":"Wolf DM, Yau C, Campbell MJ, Glas AM, Mittempergher L, Kuilman MM, et al. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): evaluation of immune subtyping in the response predictive subtypes (RPS). JCO. 2023;41(16_suppl):102\u2013102. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.102.","journal-title":"JCO"},{"issue":"3","key":"8658_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024;35(3):293\u2013301. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.018.","journal-title":"Ann Oncol"},{"issue":"1","key":"8658_CR26","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.esmoop.2023.101463","volume":"8","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Pascual T, Ortega PT, Vila MM, Cejalvo JM, Jurado JC, et al. 124O patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive\/HER2-negative (HR+\/HER2-) and triple-negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial. ESMO Open. 2023;8(1):101463. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101463.","journal-title":"ESMO Open"},{"key":"8658_CR27","doi-asserted-by":"publisher","unstructured":"Loi S, Niman S, Zdenkowski N, Francis P, Hay SB, Fox W, et al. Abstract LBO1-03: randomized phase II study of neoadjuvant nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in triple negative breast cancer (TNBC): (BCT1902\/IBCSG 61\u201320 neo-N). Cancer Res. 2024;84(9_Supplement):LBO1\u201303\u2013LBO1\u201303. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-LBO1-03.","DOI":"10.1158\/1538-7445.SABCS23-LBO1-03"},{"key":"8658_CR28","doi-asserted-by":"publisher","unstructured":"Nederlof I, Isaeva OI, Bakker N, de Graaf M, Salgado RF, Klioueva N, et al. LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial. Ann Oncol. 2022;33:S1382. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.007.","DOI":"10.1016\/j.annonc.2022.08.007"},{"issue":"16_suppl","key":"8658_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2022.40.16_suppl.602","volume":"40","author":"S Loi","year":"2022","unstructured":"Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, et al. Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): a single-arm phase 2 trial. JCO. 2022;40(16_suppl):602\u2013602. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.602.","journal-title":"JCO"},{"issue":"16_suppl","key":"8658_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2024.42.16_suppl.608","volume":"42","author":"S Loi","year":"2024","unstructured":"Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, et al. Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702\u2014survival results. JCO. 2024;42(16_suppl):608\u2013608. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.608.","journal-title":"JCO"},{"key":"8658_CR31","doi-asserted-by":"publisher","unstructured":"Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al. Abstract GS01-03: adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA\/IMpassion030 phase 3 trial. Cancer Res. 2024;84(9_Supplement):GS01\u201303\u2013GS01\u201303. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-GS01-03.","DOI":"10.1158\/1538-7445.SABCS23-GS01-03"},{"issue":"21","key":"8658_CR32","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study. JCO. 2016;34(21):2460\u201367. https:\/\/doi.org\/10.1200\/JCO.2015.64.8931.","journal-title":"JCO"},{"issue":"3","key":"8658_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517.","journal-title":"Ann Oncol"},{"issue":"3","key":"8658_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdy518.","journal-title":"Ann Oncol"},{"key":"8658_CR35","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s J, Lipatov O, Im SA, Gon\u00e7alves A, Lee KS, Schmid P, et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol. 2019;30:v859\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdz394.010.","DOI":"10.1093\/annonc\/mdz394.010"},{"issue":"4","key":"8658_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3.","journal-title":"The Lancet Oncol"},{"issue":"10265","key":"8658_CR37","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(20)32531-9.","journal-title":"Lancet"},{"issue":"1","key":"8658_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(1):74. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4224.","journal-title":"JAMA Oncol"},{"issue":"3","key":"8658_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang C-W, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol. 2019;5(3):334. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5152.","journal-title":"JAMA Oncol"},{"issue":"22","key":"8658_CR40","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"8","key":"8658_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.801.","journal-title":"Ann Oncol"},{"key":"8658_CR42","doi-asserted-by":"publisher","unstructured":"Franzoi MA, Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to explain different results? ESMO Open. 2020;5(6):e001112. https:\/\/doi.org\/10.1136\/esmoopen-2020-001112.","DOI":"10.1136\/esmoopen-2020-001112"},{"issue":"7","key":"8658_CR43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, Andr\u00e9 F, Gon\u00e7alves A, Martin M, Schmid P, Sch\u00fctz F, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35(7):630\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.001.","journal-title":"Ann Oncol"},{"key":"8658_CR44","doi-asserted-by":"publisher","unstructured":"Gion M, Cortez-Castedo P, Blancas I, Cort\u00e9s A, Marm\u00e9 F, Blanch S, et al. Abstract PS16-02: efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Cancer Res. 2024;84(9_Supplement):PS16\u201302\u2013PS16\u201302. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PS16-02.","DOI":"10.1158\/1538-7445.SABCS23-PS16-02"},{"issue":"27","key":"8658_CR45","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.18632\/oncotarget.24867","volume":"9","author":"CA Santa-Maria","year":"2018","unstructured":"Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9(27):18985\u201396. https:\/\/doi.org\/10.18632\/oncotarget.24867.","journal-title":"Oncotarget"},{"issue":"2","key":"8658_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","volume":"28","author":"S Adams","year":"2022","unstructured":"Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28(2):271\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2182.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"8658_CR47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord J-P, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. The Lancet Oncol. 2020;21(9):1155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(20)30324-7.","journal-title":"The Lancet Oncol"},{"issue":"8","key":"8658_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029.","journal-title":"JAMA Oncol"},{"issue":"7","key":"8658_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","volume":"30","author":"TJ Tan","year":"2024","unstructured":"Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, et al. Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer. Clin Cancer Res. 2024;30(7):1240\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2513.","journal-title":"Clin Cancer Res"},{"key":"8658_CR50","doi-asserted-by":"publisher","unstructured":"Rugo H, Robson M, Im SA, Dalenc F, Ruiz EY, Im Y-H, et al. Abstract GS01-05: pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study. Cancer Res. 2024;84(9_Supplement):GS01\u201305\u2013GS01\u201305. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-GS01-05.","DOI":"10.1158\/1538-7445.SABCS23-GS01-05"},{"key":"8658_CR51","doi-asserted-by":"publisher","first-page":"103220","DOI":"10.1016\/j.esmoop.2024.103220","volume":"9","author":"AL Cussac","year":"2024","unstructured":"Cussac AL, Rugo HS, Robson ME, Im S-A, Dalenc F, Ruiz EY, et al. 198P pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: patient-reported outcomes from KEYLYNK-009. ESMO Open. 2024;9:103220. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103220.","journal-title":"ESMO Open"},{"key":"8658_CR52","doi-asserted-by":"publisher","unstructured":"Gion M, Blancas I, Cortez-Castedo P, Cort\u00e9s-Salgado A, Marm\u00e9 F, Blanch S, et al. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Nat Med. 2025;31(8):2746\u201354. https:\/\/doi.org\/10.1038\/s41591-025-03734-3.","DOI":"10.1038\/s41591-025-03734-3"},{"key":"8658_CR53","doi-asserted-by":"publisher","unstructured":"Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8(1). https:\/\/doi.org\/10.1186\/1479-5876-8-71.","DOI":"10.1186\/1479-5876-8-71"},{"key":"8658_CR54","doi-asserted-by":"publisher","unstructured":"Wildiers H, Armstrong A, Cuypere E. Abstract PD14-08. primary efficacy results from AIPAC: a double-blinded, placebo controlled, randomized multina-tional phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients. Cancer Res. 2021;81. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PD14-08.","DOI":"10.1158\/1538-7445.SABCS20-PD14-08"},{"key":"8658_CR55","doi-asserted-by":"publisher","unstructured":"Forget F, Murillo SM, Ibrahim NK, Doger de Sp\u00e9ville Uribe B, Marathe O, Canon J-LR, et al. AIPAC-003: a randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg\/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization. JCO. 2024;42(16_suppl):TPS1125\u20131125. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS1125.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1125"},{"key":"8658_CR56","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ffski P, Tan DSW, Mart\u00edn M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10(2):e003776. https:\/\/doi.org\/10.1136\/jitc-2021-003776.","DOI":"10.1136\/jitc-2021-003776"},{"issue":"1","key":"8658_CR57","doi-asserted-by":"publisher","first-page":"2290787","DOI":"10.1080\/2162402x.2023.2290787","volume":"13","author":"CC Lin","year":"2024","unstructured":"Lin CC, Garralda E, Sch\u00f6ffski P, Hong DS, Siu LL, Martin M, et al. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Oncoimmunology. 2024;13(1):2290787. https:\/\/doi.org\/10.1080\/2162402x.2023.2290787.","journal-title":"Oncoimmunology"},{"issue":"12","key":"8658_CR58","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s11912-022-01339-4","volume":"24","author":"M Cejuela","year":"2022","unstructured":"Cejuela M, Vethencourt A, Pernas S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr Oncol Rep. 2022;24(12):1801\u201319. https:\/\/doi.org\/10.1007\/s11912-022-01339-4.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"8658_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","volume":"14","author":"R Ran","year":"2025","unstructured":"Ran R, Chen X, Yang J, Xu B. Immunotherapy in breast cancer: current landscape and emerging trends. Exp Hematol Oncol. 2025;14(1):77. https:\/\/doi.org\/10.1186\/s40164-025-00667-y.","journal-title":"Exp Hematol Oncol"},{"key":"8658_CR60","doi-asserted-by":"publisher","first-page":"107876","DOI":"10.1016\/j.intimp.2021.107876","volume":"98","author":"M Farshbafnadi","year":"2021","unstructured":"Farshbafnadi M, Khoshbin AP, Rezaei N. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol. 2021;98:107876. https:\/\/doi.org\/10.1016\/j.intimp.2021.107876.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"8658_CR61","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00432-021-03591-w","volume":"147","author":"M Sternschuss","year":"2021","unstructured":"Sternschuss M, Yerushalmi R, Saleh RR, Amir E, Goldvaser H. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2021;147(11):3369\u201379. https:\/\/doi.org\/10.1007\/s00432-021-03591-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"8658_CR62","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"8658_CR63","doi-asserted-by":"publisher","first-page":"600573","DOI":"10.3389\/fonc.2020.600573","volume":"10","author":"R Thomas","year":"2021","unstructured":"Thomas R, Al-Khadairi G, Decock J. Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front Oncol. 2021;10:600573. https:\/\/doi.org\/10.3389\/fonc.2020.600573.","journal-title":"Front Oncol"},{"issue":"7","key":"8658_CR64","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","volume":"21","author":"KS Saini","year":"2021","unstructured":"Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21(7):945\u201362. https:\/\/doi.org\/10.1080\/14712598.2021.1936494.","journal-title":"Expert Opin Biol Ther"},{"key":"8658_CR65","doi-asserted-by":"publisher","unstructured":"Pond\u00e9 NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1(4):e000073. https:\/\/doi.org\/10.1136\/esmoopen-2016-000073.","DOI":"10.1136\/esmoopen-2016-000073"},{"key":"8658_CR66","doi-asserted-by":"publisher","first-page":"104768","DOI":"10.1016\/j.critrevonc.2025.104768","volume":"212","author":"M-T Melissari","year":"2025","unstructured":"Melissari M-T, Papatheodoridi A, Argyriadis A, Kaparelou M, Dimopoulos MA, Zagouri F. Immunotherapy in primary hormone-receptor positive breast cancer: a systematic review. Crit Rev Oncol\/Hematol. 2025;212:104768. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104768.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"8658_CR67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, et al. Breast cancer: pathogenesis and treatments. Sig Transduct Target Ther. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Sig Transduct Target Ther"},{"key":"8658_CR68","doi-asserted-by":"publisher","first-page":"103423","DOI":"10.1016\/j.jaut.2025.103423","volume":"153","author":"Y Qi","year":"2025","unstructured":"Qi Y, Ge H, Sun X, Wei Y, Zhai J, Qian H, et al. Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer. J autoimmunity. 2025;153:103423. https:\/\/doi.org\/10.1016\/j.jaut.2025.103423.","journal-title":"J autoimmunity"},{"key":"8658_CR69","doi-asserted-by":"publisher","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAes) terminology. J Immunother Cancer. 2023;11(3):e006398. https:\/\/doi.org\/10.1136\/jitc-2022-006398.","DOI":"10.1136\/jitc-2022-006398"},{"issue":"6","key":"8658_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.37349\/etat.2020.00029","volume":"1","author":"F Miglietta","year":"2020","unstructured":"Miglietta F, Cona MS, Dieci MV, Guarneri V, La Verde N. An overview of immune checkpoint inhibitors in breast cancer. Exploration Targeted Anti-Tumor Ther. 2020;1(6):452\u201372. https:\/\/doi.org\/10.37349\/etat.2020.00029.","journal-title":"Exploration Targeted Anti-Tumor Ther"},{"issue":"5","key":"8658_CR71","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33(5):2123\u201340. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005.","journal-title":"Mol Ther"},{"issue":"1","key":"8658_CR72","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16(1):706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1.","journal-title":"Nat Commun"},{"issue":"8","key":"8658_CR73","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. Trucks: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"8658_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"8658_CR75","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56(3):552\u201366. https:\/\/doi.org\/10.1038\/s41409-020-01134-4.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"8658_CR76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321. https:\/\/doi.org\/10.1038\/s41571-024-00903-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"8658_CR77","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Zuccolotto G, Spirito AD, Rosato A, Mortara L. CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol. 2025;16:1574742. https:\/\/doi.org\/10.3389\/fimmu.2025.1574742.","journal-title":"Front Immunol"},{"issue":"6625","key":"8658_CR78","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, Wang S, Simic MS, Bhargava HK, Capponi S, Tonai Y, et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;378(6625):1194\u2013200. https:\/\/doi.org\/10.1126\/science.abq0225.","journal-title":"Science"},{"issue":"7971","key":"8658_CR79","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315. https:\/\/doi.org\/10.1038\/s41586-023-06243-w.","journal-title":"Nature"},{"issue":"4","key":"8658_CR80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang J, Chen Y, Jing Y, Green MR, Han L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol. 2023;20(4):211\u201328. https:\/\/doi.org\/10.1038\/s41571-023-00729-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"8658_CR81","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8658_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li P, Zeng X, Guo J, Zhang C, Fan Z, et al. CAR-T therapy dilemma and innovative design strategies for next generation. Cell Death Dis. 2025;16(1):211. https:\/\/doi.org\/10.1038\/s41419-025-07454-x.","journal-title":"Cell Death Dis"},{"key":"8658_CR83","doi-asserted-by":"publisher","first-page":"102868","DOI":"10.1016\/j.ctrv.2024.102868","volume":"133","author":"G Buono","year":"2025","unstructured":"Buono G, Capozzi M, Caputo R, Lauro VD, Cianniello D, Piezzo M, et al. CAR-T cell therapy for breast cancer: current status and future perspective. Cancer Treat Rev. 2025;133:102868. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102868.","journal-title":"Cancer Treat Rev"},{"key":"8658_CR84","doi-asserted-by":"publisher","first-page":"871661","DOI":"10.3389\/fimmu.2022.871661","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Chen F, Niu H, Li J, Pu Y, Yang C, et al. Chimeric antigen receptor (CAR)-T cell immunotherapy against thoracic malignancies: challenges and opportunities. Front Immunol. 2022;13:871661. https:\/\/doi.org\/10.3389\/fimmu.2022.871661.","journal-title":"Front Immunol"},{"key":"8658_CR85","doi-asserted-by":"publisher","unstructured":"Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Ther. 2020;3(3):e84. https:\/\/doi.org\/10.1002\/acg2.84.","DOI":"10.1002\/acg2.84"},{"issue":"1","key":"8658_CR86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunological Rev. 2014;257(1):83\u201390. https:\/\/doi.org\/10.1111\/imr.12125.","journal-title":"Immunological Rev"},{"issue":"12","key":"8658_CR87","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2026.03.047","volume":"189","author":"L Gattinoni","year":"2026","unstructured":"Gattinoni L, Inchingolo G, Harrer DC, Susana A, Puccio S, Slavkovic-Lukic D, et al. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell. 2026;189(12):3686\u2013700.e10. https:\/\/doi.org\/10.1016\/j.cell.2026.03.047.","journal-title":"Cell"},{"issue":"6","key":"8658_CR88","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","volume":"31","author":"C Corti","year":"2022","unstructured":"Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investigational Drugs. 2022;31(6):593\u2013605. https:\/\/doi.org\/10.1080\/13543784.2022.2054326.","journal-title":"Expert Opin Investigational Drugs"},{"issue":"1","key":"8658_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12935-024-03615-8","volume":"25","author":"HE Marei","year":"2025","unstructured":"Marei HE, Bedair K, Hasan A, Al-Mansoori L, Caratelli S, Sconocchia G, et al. Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer. Cancer Cell Int. 2025;25(1):3. https:\/\/doi.org\/10.1186\/s12935-024-03615-8.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"8658_CR90","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.7150\/ijbs.70120","volume":"18","author":"YH Yang","year":"2022","unstructured":"Yang YH, Liu JW, Lu C, Wei J-F. CAR-T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci. 2022;18(6):2609\u201326. https:\/\/doi.org\/10.7150\/ijbs.70120.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"8658_CR91","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie S, van Schalkwyk MCI, Hobbs S, Davies DM, van der Stegen SJC, Pereira ACP, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059\u201370. https:\/\/doi.org\/10.1007\/s10875-012-9689-9.","journal-title":"J Clin Immunol"},{"key":"8658_CR92","doi-asserted-by":"publisher","unstructured":"Specht JM, Maloney DG, Yeung C, Wu V, Bamdad C. Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*). JCO. 2021;39(15_suppl):TPS2663\u20132663. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS2663.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2663"},{"key":"8658_CR93","doi-asserted-by":"publisher","unstructured":"Specht JM, Lee S, Turtle C, Berger C, Veatch J, Gooley T, et al. Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. JCO. 2018;36(5_suppl):TPS79\u201379. https:\/\/doi.org\/10.1200\/JCO.2018.36.5_suppl.TPS79.","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79"},{"issue":"1","key":"8658_CR94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24(1):133. https:\/\/doi.org\/10.1186\/s12935-024-03315-3.","journal-title":"Cancer Cell Int"},{"key":"8658_CR95","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.adcanc.2023.100090","volume":"7","author":"A Dey","year":"2023","unstructured":"Dey A, Ghosh S, Jha S, Hazra S, Srivastava N, Chakraborty U, et al. Recent advancement in breast cancer treatment using CAR T cell therapy: - a review. Adv Cancer Biol - Metastasis. 2023;7:100090. https:\/\/doi.org\/10.1016\/j.adcanc.2023.100090.","journal-title":"Adv Cancer Biol - Metastasis"},{"key":"8658_CR96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/EDBK_180328","volume":"37","author":"O Yeku","year":"2017","unstructured":"Yeku O, Li X, Brentjens RJ. Adoptive T-Cell therapy for solid tumors. Am Soc Clin Oncol Educ Book. 2017;37:193\u2013204. https:\/\/doi.org\/10.1200\/EDBK_180328.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"8658_CR97","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193(2):216\u201330. https:\/\/doi.org\/10.1111\/bjh.17186.","journal-title":"Br J Haematol"},{"key":"8658_CR98","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135. https:\/\/doi.org\/10.3389\/fimmu.2021.732135.","journal-title":"Front Immunol"},{"key":"8658_CR99","doi-asserted-by":"publisher","first-page":"102943","DOI":"10.1016\/j.ctrv.2025.102943","volume":"137","author":"N Wu","year":"2025","unstructured":"Wu N, Yang N, Zhang S, Wu H, Fang X, Lin W, et al. Chimeric antigen receptor NK cells for breast cancer immunotherapy. Cancer Treat Rev. 2025;137:102943. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102943.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"8658_CR100","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol. 2021;18(9):2083\u2013100. https:\/\/doi.org\/10.1038\/s41423-021-00732-6.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"8658_CR101","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331. https:\/\/doi.org\/10.1038\/s41423-024-01145-x.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8658_CR102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"8658_CR103","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.3390\/ijms24109038","volume":"24","author":"MJ Raftery","year":"2023","unstructured":"Raftery MJ, Franz\u00e9n AS, Radecke C, Boulifa A, Sch\u00f6nrich G, Stintzing S, et al. Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer. IJMS. 2023;24(10):9038. https:\/\/doi.org\/10.3390\/ijms24109038.","journal-title":"IJMS"},{"issue":"9","key":"8658_CR104","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/cas.14993","volume":"112","author":"F Marofi","year":"2021","unstructured":"Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, et al. CAR-NK cell in cancer immunotherapy; a promising frontier. Cancer Sci. 2021;112(9):3427\u201336. https:\/\/doi.org\/10.1111\/cas.14993.","journal-title":"Cancer Sci"},{"issue":"2","key":"8658_CR105","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1158\/2326-6066.Cir-20-1023","volume":"10","author":"M Klopotowska","year":"2022","unstructured":"Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-Modified NK cells under oxidative stress. Cancer Immunol Res. 2022;10(2):228\u201344. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-1023.","journal-title":"Cancer Immunol Res"},{"key":"8658_CR106","doi-asserted-by":"publisher","unstructured":"Jan CI, Huang SW, Canoll P, Bruce JN, Lin Y-C, Pan C-M, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021;9(10):e003050. https:\/\/doi.org\/10.1136\/jitc-2021-003050.","DOI":"10.1136\/jitc-2021-003050"},{"issue":"1","key":"8658_CR107","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10(1):40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9.","journal-title":"Cell Death Discov"},{"key":"8658_CR108","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhou Y, Huang KH, Fang X, Li Y, Wang F, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. Cell Proliferation. 2020;53(8):e12858. https:\/\/doi.org\/10.1111\/cpr.12858.","DOI":"10.1111\/cpr.12858"},{"issue":"19","key":"8658_CR109","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7(19):27764\u201377. https:\/\/doi.org\/10.18632\/oncotarget.8526.","journal-title":"Oncotarget"},{"issue":"1","key":"8658_CR110","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):2815. https:\/\/doi.org\/10.1038\/s41598-020-59736-3.","journal-title":"Sci Rep"},{"key":"8658_CR111","doi-asserted-by":"publisher","unstructured":"Moore F, Alvarez A, Barandiaran A, et al. 264 allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and tGF\u00df dominant negative receptor effectively control HER2+ tumors. J Immunother Cancer. 2022;10(Suppl 2):A279. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0264.","DOI":"10.1136\/jitc-2022-SITC2022.0264"},{"key":"8658_CR112","doi-asserted-by":"publisher","unstructured":"Eitler J, Ben-Horin I, Freudenberg K, et al. 256 dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss. J Immunother Cancer. 2024;12(Suppl 2):A294. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0256.","DOI":"10.1136\/jitc-2024-SITC2024.0256"},{"key":"8658_CR113","doi-asserted-by":"publisher","unstructured":"Eitler J, Rackwitz W, Wotschel N, Gudipati V, Murali Shankar N, Sidorenkova A, et al. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. J Immunother Cancer. 2024;12(2):e008155. https:\/\/doi.org\/10.1136\/jitc-2023-008155.","DOI":"10.1136\/jitc-2023-008155"},{"key":"8658_CR114","doi-asserted-by":"publisher","unstructured":"Rhee Y-H, Chae H-S, Kim M, et al. 296 HER2-specific highly scalable CAR NK cell (anti-HER2-CAR SNK02) exhibits a significantly enhanced antitumor activity against HER2-expressing tumors as an off-the-shelf allogeneic immune cell therapy. J Immunother Cancer. 2023;11(Suppl 1):A339. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0296.","DOI":"10.1136\/jitc-2023-SITC2023.0296"},{"issue":"1","key":"8658_CR115","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11(1):103. https:\/\/doi.org\/10.1186\/s40364-023-00537-x.","journal-title":"Biomark Res"},{"issue":"1","key":"8658_CR116","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"8658_CR117","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"8658_CR118","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121(10):837\u201345. https:\/\/doi.org\/10.1038\/s41416-019-0578-3.","journal-title":"Br J Cancer"},{"key":"8658_CR119","doi-asserted-by":"publisher","unstructured":"Blumenthal D, Gabitova L, Menchel B, et al. 104 development and characterization of human chimeric antigen receptor monocytes (CAR-Mono), a novel cell therapy platform. J Immunother Cancer. 2021;9(Suppl 2):A114. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.104.","DOI":"10.1136\/jitc-2021-SITC2021.104"},{"issue":"21","key":"8658_CR120","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1097\/cm9.0000000000002944","volume":"137","author":"B Yang","year":"2024","unstructured":"Yang B, Wang X, Wei X, Ma J. Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy. Chin Med J. 2024;137(21):2590\u2013602. https:\/\/doi.org\/10.1097\/cm9.0000000000002944.","journal-title":"Chin Med J"},{"issue":"16_suppl","key":"8658_CR121","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","volume":"40","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, Yuan Y, Ueno NT, Johnson ML, Gill S, Dees EC, et al. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. JCO. 2022;40(16_suppl):2533\u20132533. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2533.","journal-title":"JCO"},{"issue":"3","key":"8658_CR122","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","volume":"22","author":"M Lopez de Rodas","year":"2025","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025;22(3):163\u201381. https:\/\/doi.org\/10.1038\/s41571-024-00984-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"8658_CR123","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41416-023-02321-y","volume":"129","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. Br J Cancer. 2023;129(7):1041\u201349. https:\/\/doi.org\/10.1038\/s41416-023-02321-y.","journal-title":"Br J Cancer"},{"key":"8658_CR124","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.breast.2022.10.001","volume":"66","author":"S Li","year":"2022","unstructured":"Li S, Zhang Y, Zhang P, Xue S, Chen Y, Sun L, et al. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis. Breast. 2022;66:97\u2013109. https:\/\/doi.org\/10.1016\/j.breast.2022.10.001.","journal-title":"Breast"},{"issue":"16","key":"8658_CR125","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/jco.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. JCO. 2022;40(16):1741\u201354. https:\/\/doi.org\/10.1200\/jco.21.02170.","journal-title":"JCO"},{"issue":"10","key":"8658_CR126","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"R Hong","year":"2022","unstructured":"Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun. 2022;42(10):913\u201336. https:\/\/doi.org\/10.1002\/cac2.12358.","journal-title":"Cancer Commun"},{"issue":"27","key":"8658_CR127","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. JCO. 2014;32(27):2959\u201366. https:\/\/doi.org\/10.1200\/JCO.2013.55.0491.","journal-title":"JCO"},{"key":"8658_CR128","doi-asserted-by":"publisher","unstructured":"Fernandes I, Scorsato A, Kaliks R, Corpa M, Damasceno E, Schvartsman G. Tumor-infiltrating lymphocytes in HER2-low breast cancer. Clin Breast Cancer. 2023;23(7):e470\u201379. https:\/\/doi.org\/10.1016\/j.clbc.2023.07.007.","DOI":"10.1016\/j.clbc.2023.07.007"},{"issue":"1","key":"8658_CR129","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. The Lancet Oncol. 2018;19(1):40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"8658_CR130","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10549-023-07233-2","volume":"205","author":"SJ Wood","year":"2024","unstructured":"Wood SJ, Gao Y, Lee J-H, Chen J, Wang Q, Meisel JL, et al. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res Treat. 2024;205(1):193\u201399. https:\/\/doi.org\/10.1007\/s10549-023-07233-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"8658_CR131","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y-C, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724\u201330. https:\/\/doi.org\/10.1038\/s41591-018-0040-8.","journal-title":"Nat Med"},{"issue":"13","key":"8658_CR132","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331(13):1135\u201344. https:\/\/doi.org\/10.1001\/jama.2024.3056.","journal-title":"JAMA"},{"issue":"7","key":"8658_CR133","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/jco.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. JCO. 2019;37(7):559\u201369. https:\/\/doi.org\/10.1200\/jco.18.01010.","journal-title":"JCO"},{"issue":"4","key":"8658_CR134","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2024.6872","volume":"11","author":"MV Dieci","year":"2025","unstructured":"Dieci MV, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A, et al. Tumor-infiltrating lymphocytes and survival outcomes in early ERBB2 -positive breast cancer. JAMA Oncol. 2025;11(4):386\u201393. https:\/\/doi.org\/10.1001\/jamaoncol.2024.6872.","journal-title":"JAMA Oncol"},{"issue":"14","key":"8658_CR135","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.18.02157","volume":"37","author":"A Kov\u00e1cs","year":"2019","unstructured":"Kov\u00e1cs A, Tullberg AS, R\u00f6nnerman EW, Holmberg E, Hartman L, Sj\u00f6str\u00f6m M, et al. Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. JCO. 2019;37(14):1179\u201387. https:\/\/doi.org\/10.1200\/JCO.18.02157.","journal-title":"JCO"},{"issue":"4","key":"8658_CR136","doi-asserted-by":"publisher","first-page":"20210058","DOI":"10.1002\/EXP.20210058","volume":"3","author":"S Du","year":"2023","unstructured":"Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Exploration. 2023;3(4):20210058. https:\/\/doi.org\/10.1002\/EXP.20210058.","journal-title":"Exploration"},{"key":"8658_CR137","doi-asserted-by":"publisher","first-page":"1493346","DOI":"10.3389\/fphar.2025.1493346","volume":"16","author":"W He","year":"2025","unstructured":"He W, Cui K, Farooq MA, Huang N, Zhu S, Jiang D, et al. TCR-T cell therapy for solid tumors: challenges and emerging solutions. Front Pharmacol. 2025;16:1493346. https:\/\/doi.org\/10.3389\/fphar.2025.1493346.","journal-title":"Front Pharmacol"},{"key":"8658_CR138","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-Engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol"},{"key":"8658_CR139","doi-asserted-by":"publisher","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","DOI":"10.1126\/sciadv.adf3700"},{"issue":"1","key":"8658_CR140","doi-asserted-by":"publisher","first-page":"1777046","DOI":"10.1080\/2162402x.2020.1777046","volume":"9","author":"R Sommaggio","year":"2020","unstructured":"Sommaggio R, Cappuzzello E, Piet\u00e0 AD, Tosi A, Palmerini P, Carpanese D, et al. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology. 2020;9(1):1777046. https:\/\/doi.org\/10.1080\/2162402x.2020.1777046.","journal-title":"Oncoimmunology"},{"issue":"1","key":"8658_CR141","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13287-024-03869-z","volume":"15","author":"F Ghanbari Sevari","year":"2024","unstructured":"Ghanbari Sevari F, Mehdizadeh A, Abbasi K, Hejazian SS, Raeisi M. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies. STEM Cell Res Ther. 2024;15(1):254. https:\/\/doi.org\/10.1186\/s13287-024-03869-z.","journal-title":"STEM Cell Res Ther"},{"issue":"12","key":"8658_CR142","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cellular Physiol. 2020;235(12):9291\u2013303. https:\/\/doi.org\/10.1002\/jcp.29827.","journal-title":"J Cellular Physiol"},{"issue":"10","key":"8658_CR143","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s12094-013-1001-9","volume":"15","author":"J Ren","year":"2013","unstructured":"Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol. 2013;15(10):780\u201388. https:\/\/doi.org\/10.1007\/s12094-013-1001-9.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"8658_CR144","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-14-0082","volume":"20","author":"K Pan","year":"2014","unstructured":"Pan K, Guan X-X, Li Y-Q, Zhao J-J, Li J-J, Qiu H-J, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with Post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20(11):3003\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0082.","journal-title":"Clin Cancer Res"},{"key":"8658_CR145","doi-asserted-by":"publisher","unstructured":"Hu J, Hu J, Liu X, Hu C, Li M, Han W. Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: a meta-analysis. Med (Baltim). 2017;96(42):e8310. https:\/\/doi.org\/10.1097\/md.0000000000008310.","DOI":"10.1097\/md.0000000000008310"},{"key":"8658_CR146","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.imlet.2017.01.014","volume":"183","author":"M Lin","year":"2017","unstructured":"Lin M, Liang S, Jiang F, Xu J, Zhu W, Qian W, et al. 2003\u20132013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. Immunol Lett. 2017;183:37\u201343. https:\/\/doi.org\/10.1016\/j.imlet.2017.01.014.","journal-title":"Immunol Lett"},{"issue":"1","key":"8658_CR147","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s40425-019-0696-8","volume":"7","author":"ZQ Zhou","year":"2019","unstructured":"Zhou ZQ, Zhao JJ, Pan QZ, Chen C-L, Liu Y, Tang Y, et al. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J. Immunother Cancer. 2019;7(1):228. https:\/\/doi.org\/10.1186\/s40425-019-0696-8.","journal-title":"J. Immunother Cancer"},{"issue":"5","key":"8658_CR148","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-016-1815-8","volume":"65","author":"SL Poh","year":"2016","unstructured":"Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. ImmunotherapyCancer Immunol Immunother. 2016;65(5):525\u201336. https:\/\/doi.org\/10.1007\/s00262-016-1815-8.","journal-title":"ImmunotherapyCancer Immunol Immunother"},{"key":"8658_CR149","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","volume":"201","author":"FV Suurs","year":"2019","unstructured":"Suurs FV, Hooge MNL-D, de Vries EGE, de Groot DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103\u201319. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.006.","journal-title":"Pharmacol Ther"},{"issue":"2\u20133","key":"8658_CR150","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12026-014-8507-2","volume":"58","author":"TL Schmidt","year":"2014","unstructured":"Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. Immunol Res. 2014;58(2\u20133):300\u201306. https:\/\/doi.org\/10.1007\/s12026-014-8507-2.","journal-title":"Immunol Res"},{"key":"8658_CR151","doi-asserted-by":"publisher","unstructured":"Liu S, Meng Y, Liu L, Lv Y, Yu W, Liu T, et al. CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death Dis. 2022;13(5). https:\/\/doi.org\/10.1038\/s41419-022-04882-x.","DOI":"10.1038\/s41419-022-04882-x"},{"issue":"3","key":"8658_CR152","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbmt.2004.11.019","volume":"11","author":"T Leemhuis","year":"2005","unstructured":"Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11(3):181\u201387. https:\/\/doi.org\/10.1016\/j.bbmt.2004.11.019.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"8658_CR153","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/14653249.2012.694419","volume":"14","author":"YC Linn","year":"2012","unstructured":"Linn YC, Yong HX, Niam M, Lim T-J, Chu S, Choong A, et al. A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012;14(7):851\u201359. https:\/\/doi.org\/10.3109\/14653249.2012.694419.","journal-title":"Cytotherapy"},{"issue":"9","key":"8658_CR154","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/CJI.0000000000000001","volume":"36","author":"Q Tao","year":"2013","unstructured":"Tao Q, Chen T, Tao L, Wang H, Pan Y, Xiong S, et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+ CD56+ cells and downregulating regulatory T cells as well as IL-35. J Immunother. 2013;36(9):462\u201367. https:\/\/doi.org\/10.1097\/CJI.0000000000000001.","journal-title":"J Immunother"},{"key":"8658_CR155","doi-asserted-by":"publisher","unstructured":"Cappuzzello E, Vigolo E, D\u2019Accardio G, Astori G, Rosato A, Sommaggio R. How can cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1229540.","DOI":"10.3389\/fimmu.2023.1229540"},{"issue":"4","key":"8658_CR156","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.it.2015.02.007","volume":"36","author":"PJ Siska","year":"2015","unstructured":"Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36(4):257\u201364. https:\/\/doi.org\/10.1016\/j.it.2015.02.007.","journal-title":"Trends Immunol"},{"issue":"23","key":"8658_CR157","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.3390\/cancers13236012","volume":"13","author":"K Retecki","year":"2021","unstructured":"Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance. Cancers (Basel). 2021;13(23):6012. https:\/\/doi.org\/10.3390\/cancers13236012.","journal-title":"Cancers (Basel)"},{"key":"8658_CR158","doi-asserted-by":"publisher","first-page":"104389","DOI":"10.1016\/j.critrevonc.2024.104389","volume":"199","author":"OH Rodr\u00edguez-Bejarano","year":"2024","unstructured":"Rodr\u00edguez-Bejarano OH, Parra-L\u00f3pez C, Patarroyo MA. A review concerning the breast cancer-related tumour microenvironment. Crit Rev Oncol\/Hematol. 2024;199:104389. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104389.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"8658_CR159","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-021-06337-x","volume":"190","author":"A Hanna","year":"2021","unstructured":"Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190(1):5\u201317. https:\/\/doi.org\/10.1007\/s10549-021-06337-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8658_CR160","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266. https:\/\/doi.org\/10.1186\/s12943-024-02176-8.","journal-title":"Mol Cancer"},{"issue":"6","key":"8658_CR161","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/cancers18060911","volume":"18","author":"I Tsagkaraki","year":"2026","unstructured":"Tsagkaraki I, Gannon I, Rampotas A, Singh D, Roddy H, Ottaviani D, et al. Immunotherapies for breast cancer: from checkpoint inhibition to emerging cellular therapies. Cancers. 2026;18(6):911. https:\/\/doi.org\/10.3390\/cancers18060911.","journal-title":"Cancers"},{"key":"8658_CR162","doi-asserted-by":"publisher","first-page":"599207","DOI":"10.3389\/fimmu.2021.599207","volume":"12","author":"Q Liu","year":"2021","unstructured":"Liu Q, Qi Y, Zhai J, Kong X, Wang X, Wang Z, et al. Molecular and clinical characterization of LAG3 in breast cancer through 2994 samples. Front Immunol. 2021;12:599207. https:\/\/doi.org\/10.3389\/fimmu.2021.599207.","journal-title":"Front Immunol"},{"issue":"1","key":"8658_CR163","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"8658_CR164","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2174\/1386207325666220629162823","volume":"26","author":"C Guo","year":"2023","unstructured":"Guo C, Luo Z, Ismtula D, Bi X, Kong H, Wang Y, et al. TIGIT as a novel prognostic Marker for immune infiltration in invasive breast cancer. CCHTS. 2023;26(3):639\u201351. https:\/\/doi.org\/10.2174\/1386207325666220629162823.","journal-title":"CCHTS"},{"issue":"8","key":"8658_CR165","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jcyt.2014.03.005","volume":"16","author":"P Hourd","year":"2014","unstructured":"Hourd P, Ginty P, Chandra A, Williams DJ. Manufacturing models permitting roll out\/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy. 2014;16(8):1033\u201347. https:\/\/doi.org\/10.1016\/j.jcyt.2014.03.005.","journal-title":"Cytotherapy"},{"issue":"4","key":"8658_CR166","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3343\/alm.2023.0382","volume":"44","author":"NK Lee","year":"2024","unstructured":"Lee NK, Chang JW. Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med. 2024;44(4):314\u201323. https:\/\/doi.org\/10.3343\/alm.2023.0382.","journal-title":"Ann Lab Med"},{"issue":"5","key":"8658_CR167","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00281-024-01019-4","volume":"46","author":"A Ramamurthy","year":"2024","unstructured":"Ramamurthy A, Tommasi A, Saha K. Advances in manufacturing chimeric antigen receptor immune cell therapies. Semin Immunopathol. 2024;46(5):12. https:\/\/doi.org\/10.1007\/s00281-024-01019-4.","journal-title":"Semin Immunopathol"},{"key":"8658_CR168","doi-asserted-by":"publisher","unstructured":"Chen R, Johnson J, Rezazadeh A, Dudek AZ. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. bmjonc. 2025;4(1):e000566. https:\/\/doi.org\/10.1136\/bmjonc-2024-000566.","DOI":"10.1136\/bmjonc-2024-000566"},{"issue":"6","key":"8658_CR169","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/08830185.2022.2067154","volume":"41","author":"HW Song","year":"2022","unstructured":"Song HW, Somerville RP, Stroncek DF, Highfill SL. Scaling up and scaling out: advances and challenges in manufacturing engineered T cell therapies. Int Rev Immunol. 2022;41(6):638\u201348. https:\/\/doi.org\/10.1080\/08830185.2022.2067154.","journal-title":"Int Rev Immunol"},{"issue":"4","key":"8658_CR170","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.stem.2025.03.004","volume":"32","author":"T Deuse","year":"2025","unstructured":"Deuse T, Schrepfer S. Progress and challenges in developing allogeneic cell therapies. Cell STEM Cell. 2025;32(4):513\u201328. https:\/\/doi.org\/10.1016\/j.stem.2025.03.004.","journal-title":"Cell STEM Cell"},{"issue":"1","key":"8658_CR171","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12967-022-03238-5","volume":"20","author":"DF Stroncek","year":"2022","unstructured":"Stroncek DF, Somerville RPT, Highfill SL. Point-of-care cell therapy manufacturing; it\u2019s not for everyone. J Transl Med. 2022;20(1):34. https:\/\/doi.org\/10.1186\/s12967-022-03238-5.","journal-title":"J Transl Med"},{"key":"8658_CR172","doi-asserted-by":"publisher","first-page":"1644318","DOI":"10.3389\/fbioe.2025.1644318","volume":"13","author":"YS Chiu","year":"2025","unstructured":"Chiu YS, Wang KL, Wu KL. Isolator-based point-of-care manufacturing: a practical solution for GMP-compliant cell and extracellular vesicles therapy production. Front Bioeng Biotechnol. 2025;13:1644318. https:\/\/doi.org\/10.3389\/fbioe.2025.1644318.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"8658_CR173","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nbt.3525","volume":"34","author":"YY Lipsitz","year":"2016","unstructured":"Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393\u2013400. https:\/\/doi.org\/10.1038\/nbt.3525.","journal-title":"Nat Biotechnol"},{"issue":"38","key":"8658_CR174","doi-asserted-by":"publisher","first-page":"50139","DOI":"10.1021\/acsami.4c06183","volume":"16","author":"E P\u00e9rez Del R\u00edo","year":"2024","unstructured":"P\u00e9rez Del R\u00edo E, Rey-Vinolas S, Santos F, Castellote-Borrell M, Merlina F, Veciana J, et al. 3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture. ACS Appl Mater Interface. 2024;16(38):50139\u201346. https:\/\/doi.org\/10.1021\/acsami.4c06183.","journal-title":"ACS Appl Mater Interface"},{"key":"8658_CR175","doi-asserted-by":"publisher","first-page":"1613836","DOI":"10.3389\/fbioe.2025.1613836","volume":"13","author":"A Nikoniuk","year":"2025","unstructured":"Nikoniuk A, Lilova K, Thomas M, Szita N. The potential of microfluidic cell analysis in CAR T cell therapy manufacturing. Front Bioeng Biotechnol. 2025;13:1613836. https:\/\/doi.org\/10.3389\/fbioe.2025.1613836.","journal-title":"Front Bioeng Biotechnol"},{"key":"8658_CR176","doi-asserted-by":"publisher","unstructured":"Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-Cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40(40):e27\u201334. https:\/\/doi.org\/10.1200\/edbk_279151.","DOI":"10.1200\/edbk_279151"},{"issue":"36","key":"8658_CR177","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. JCO. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"JCO"},{"issue":"1","key":"8658_CR178","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13181-021-00835-6","volume":"18","author":"N Chhabra","year":"2022","unstructured":"Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity II: adoptive cellular therapies, kinase inhibitors, monoclonal antibodies, and oncolytic viruses. J Med Toxicol. 2022;18(1):43\u201355. https:\/\/doi.org\/10.1007\/s13181-021-00835-6.","journal-title":"J Med Toxicol"},{"issue":"1","key":"8658_CR179","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478.","journal-title":"Ann Oncol"},{"issue":"1","key":"8658_CR180","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z.","journal-title":"Mol Cancer"},{"key":"8658_CR181","doi-asserted-by":"publisher","unstructured":"Wang Z, Miao L, Wang W. The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1698146.","DOI":"10.3389\/fimmu.2025.1698146"},{"key":"8658_CR182","doi-asserted-by":"publisher","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","DOI":"10.3389\/fphar.2014.00235"},{"key":"8658_CR183","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.breast.2025.104545","volume":"83","author":"M Li","year":"2025","unstructured":"Li M, Panet F, Barberi V, Salgado R, Oliveira M, Loi S. Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer. Breast. 2025;83:104545. https:\/\/doi.org\/10.1016\/j.breast.2025.104545.","journal-title":"Breast"},{"issue":"6","key":"8658_CR184","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"8658_CR185","doi-asserted-by":"publisher","unstructured":"Liang Y, Wu K, Pan L, Jia M, Zhang W, Zhang X, et al. Tertiary lymphoid structures in breast cancer: mechanistic insights, subtype-specific patterns, and therapeutic implications. World J Surg Onc. 2026. https:\/\/doi.org\/10.1186\/s12957-026-04467-4.","DOI":"10.1186\/s12957-026-04467-4"},{"key":"8658_CR186","doi-asserted-by":"publisher","first-page":"868155","DOI":"10.3389\/fimmu.2022.868155","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Liu J, Han Y, Deng Y, Li J, Jiang Y. The presence of tertiary lymphoid structures provides new insight into the clinicopathological features and prognosis of patients with breast cancer. Front Immunol. 2022;13:868155. https:\/\/doi.org\/10.3389\/fimmu.2022.868155.","journal-title":"Front Immunol"},{"issue":"2","key":"8658_CR187","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1309\/ajcpixuydvz0rz3g","volume":"144","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn J-H, et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am J Clin Pathol. 2015;144(2):278\u201388. https:\/\/doi.org\/10.1309\/ajcpixuydvz0rz3g.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"8658_CR188","doi-asserted-by":"publisher","first-page":"101004","DOI":"10.1016\/j.modpat.2026.101004","volume":"39","author":"S Yu","year":"2026","unstructured":"Yu S, Dekker M, Zwager MC, Slagter-Menkema L, van der Sluis T, Schr\u00f6der CP, et al. Mature tertiary lymphoid structures in breast cancers are associated with antitumor immunity and better prognosis. Mod Pathol. 2026;39(6):101004. https:\/\/doi.org\/10.1016\/j.modpat.2026.101004.","journal-title":"Mod Pathol"},{"key":"8658_CR189","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 391(21):1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932. September 15, 2024.","DOI":"10.1056\/NEJMoa2409932"},{"issue":"8","key":"8658_CR190","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cac2.12447","volume":"43","author":"F Bertucci","year":"2023","unstructured":"Bertucci F, Nonneville AD, Finetti P, Mamessier E. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer. Cancer Commun (Lond). 2023;43(8):943\u201346. https:\/\/doi.org\/10.1002\/cac2.12447.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"8658_CR191","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","volume":"132","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu Y, Wang C, Jiang Z, Li J, Li X, et al. Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer. Br J Cancer. 2025;132(3):295\u2013310. https:\/\/doi.org\/10.1038\/s41416-024-02917-y.","journal-title":"Br J Cancer"},{"issue":"2","key":"8658_CR192","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10549-022-06787-x","volume":"197","author":"S Yazaki","year":"2023","unstructured":"Yazaki S, Shimoi T, Yoshida M, Sumiyoshi-Okuma H, Arakaki M, Saito A, et al. Integrative prognostic analysis of tumor\u2013infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. Breast Cancer Res Treat. 2023;197(2):287\u201397. https:\/\/doi.org\/10.1007\/s10549-022-06787-x.","journal-title":"Breast Cancer Res Treat"},{"key":"8658_CR193","doi-asserted-by":"publisher","unstructured":"Cho KS, Liu Y, Pei G, Chen J, Dai Y, Liu Y, et al. Pan-cancer spatial atlas of tertiary lymphoid structures. Science. 2026;392(6801):eadz2742. https:\/\/doi.org\/10.1126\/science.adz2742.","DOI":"10.1126\/science.adz2742"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08658-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:24Z","timestamp":1785521364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08658-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":193,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8658"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08658-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.M. is an Associate Editor of the\n                      Journal of Translational Medicine\n                      . F.M.M. is the Editor-in-Chief of the\n                      Journal of Translational Medicine\n                      . Given the role as Editor-In-Chief and Associate Editor A.M. and F.M.M had no involvement in the peer review of this paper and had no access to information regarding its peer-review process. Full responsibility for the editorial process of this paper was delegated to another editor of the journal. F.M.M is also an employee of Translational and Advanced Medicine (TAM) Biosciences, Nashville, TN, USA. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"971"}}